2.Selection and validation of reference genes for quantitative real-time PCR analysis in Tujia medicine Xuetong.
Qian XIAO ; Chen-Si TAN ; Jiang ZENG ; Yuan-Shu XU ; Tian-Hao FU ; Lu-Yun NING ; Wei WANG
China Journal of Chinese Materia Medica 2025;50(3):682-692
Tujia ethnic group medicine Xuetong is derived from Kadsura heteroclita, the stem of which has the medicinal value for anti-rheumatoid arthritis, liver protection, anti-tumor, anti-oxidation effects, and has been widely used in Hunan and Guangdong in China. The selection of reliable and stable reference genes is the basis for subsequent molecular research on K. heteroclita. In this study, GAPDH, TUA, Actin, UBQ, EF-1α, 18S-rRNA, CYP, UBC, TUB, H2A, and RPL were selected as candidate reference genes in Kadsura heteroclita. The gene expression levels of the 11 candidate reference genes of K. heteroclita in its 6 different parts(stem-inside of the cambium, stem-outside of the cambium, fruit, flower, root, and leaf) and under different intervention conditions [drought stress, salt stress, and methyl jasmonate(MeJA) treatment] were detected by quantitative real-time polymerase chain reaction(qRT-PCR). The expression stability of the 11 candidate reference genes was comprehensively analyzed and evaluated by geNorm, NormFinder, ΔCT algorithm, and RefFinder software. The results showed that the expression of UBC and RPL was relatively stable in 6 different parts, and UBC and GAPDH genes were relatively stable under different intervention conditions. To verify the reliability of reference genes for K. heteroclita, this study further examined the relative expression levels of KhFPS, KhIDI, KhCAS, KhSQE, KhSQS, KhSQS-2, KhHMGS, KhHMGR, KhMVD, KhMVK, KhDXR, KhDXS, KhPMVK, and KhGGPS in different parts and under different intervention conditions, which might relate to the synthesis of the main component(Xuetongsu) of K. heteroclita. The results showed that with UBC and RPL or UBC and GAPDH as the reference genes, the expression trends of these 14 genes were basically consistent in different parts or under different intervention conditions for K. heteroclita. In conclusion, UBC can be used as a reference gene of K. heteroclita for its different parts and different intervention conditions, which lays a foundation for further research on the biosynthetic pathway of main components in K. heteroclita.
Real-Time Polymerase Chain Reaction/methods*
;
Reference Standards
;
Gene Expression Regulation, Plant
;
Gene Expression Profiling
;
Plant Proteins/metabolism*
;
Drugs, Chinese Herbal
3.Revision and prospect of "Standards for indoor air quality(GB/T 18883-2022)" in China.
Chinese Journal of Preventive Medicine 2023;57(11):1725-1728
The formulation and revision of the detection methods of indoor air quality standards is an important, rigorous and delicate endeavor. The standards for indoor air quality (GB/T 18883-2022) were issued by the State Administration of Market Regulation and the Standardization Administration on July 11, 2022, and implemented on February 1, 2023 by replacing indoor air quality standards (GB/T 18883-2002). The revised standard specifies hygienic requirements for physical, chemical, biological and radioactive indicators in indoor air and the corresponding test methods. This article interpreted the revision background, drafting principles, main indicators and methods, as well as the revision basis of the standards. Recommendations for the implementation of the standards are also proposed.
Humans
;
Air Pollution, Indoor/prevention & control*
;
Environmental Monitoring
;
Reference Standards
;
China
;
Air Pollutants/analysis*
4.Study on formulation and revision of detection methods of "Standards for indoor air quality (GB/T 18883-2022)" in China.
Hai Jing ZHANG ; Yi Fu LU ; Qin WANG ; Yan Wei YANG ; Yun Pu LI ; Yun Yun WU ; Cheng DING ; Jun Rui CHANG ; Ying ZHU ; Dong Qun XU
Chinese Journal of Preventive Medicine 2023;57(11):1777-1781
The formulation and revision of the detection methods of indoor air quality standards is an important, rigorous and delicate endeavor. This paper introduced the formulation and revision of the detection methods of the standards for indoor air quality (GB/T 18883-2022), focusing on the revision process, revision principles, main adjustments and technical points of some key indicators to facilitate users to better understand and apply the detection methods in standards for indoor air quality (GB/T 18883-2022).
Humans
;
Air Pollution, Indoor
;
China
;
Reference Standards
;
Air Pollutants/analysis*
5.Appropriate range of body mass index and body weight management guidelines for Chinese oldest old (T/CNSS 021-2023).
Chinese Journal of Epidemiology 2023;44(9):1335-1337
Body mass index (BMI) is widely recognized as an important indicator of physical health. However, the current BMI standard and guidelines primarily focus on children and general adults, neglecting the specific needs of the oldest old aged 80 years or older. To address this gap, this guideline aims to provide recommendations on the appropriate range of BMI and weight management for the oldest old in China, including age calculation, defining the appropriate BMI range, BMI measurement indicators, and weight management strategies. It is intended to be utilized by medical and health organizations at all levels, as well as medical and nursing service institutions, to evaluate the BMI and manage the weight of the oldest old population.
Aged, 80 and over
;
Humans
;
Asian People
;
Body Mass Index
;
Body Weight
;
China
;
East Asian People
;
Reference Values
;
Health Promotion/standards*
6.Revision and prospect of "Standards for indoor air quality(GB/T 18883-2022)" in China.
Chinese Journal of Preventive Medicine 2023;57(11):1725-1728
The formulation and revision of the detection methods of indoor air quality standards is an important, rigorous and delicate endeavor. The standards for indoor air quality (GB/T 18883-2022) were issued by the State Administration of Market Regulation and the Standardization Administration on July 11, 2022, and implemented on February 1, 2023 by replacing indoor air quality standards (GB/T 18883-2002). The revised standard specifies hygienic requirements for physical, chemical, biological and radioactive indicators in indoor air and the corresponding test methods. This article interpreted the revision background, drafting principles, main indicators and methods, as well as the revision basis of the standards. Recommendations for the implementation of the standards are also proposed.
Humans
;
Air Pollution, Indoor/prevention & control*
;
Environmental Monitoring
;
Reference Standards
;
China
;
Air Pollutants/analysis*
7.Study on formulation and revision of detection methods of "Standards for indoor air quality (GB/T 18883-2022)" in China.
Hai Jing ZHANG ; Yi Fu LU ; Qin WANG ; Yan Wei YANG ; Yun Pu LI ; Yun Yun WU ; Cheng DING ; Jun Rui CHANG ; Ying ZHU ; Dong Qun XU
Chinese Journal of Preventive Medicine 2023;57(11):1777-1781
The formulation and revision of the detection methods of indoor air quality standards is an important, rigorous and delicate endeavor. This paper introduced the formulation and revision of the detection methods of the standards for indoor air quality (GB/T 18883-2022), focusing on the revision process, revision principles, main adjustments and technical points of some key indicators to facilitate users to better understand and apply the detection methods in standards for indoor air quality (GB/T 18883-2022).
Humans
;
Air Pollution, Indoor
;
China
;
Reference Standards
;
Air Pollutants/analysis*
8.Updated growth standards for Chinese children under 7 years of age.
Xin Nan ZONG ; Hui LI ; Ya Qin ZHANG ; Hua Hong WU
Chinese Journal of Pediatrics 2023;61(12):1103-1108
Objective: To construct growth standards for Chinese children under 7 years of age. Methods: Cross-sectional study design based on national representative data on children's growth and development in 2015 was used. Stratified cluster sampling method was used. A total of 83 628 healthy children aged 0-<7 years from 9 cities, including Beijing, Harbin, Xi'an, Shanghai, Nanjing, Wuhan, Guangzhou, Fuzhou, and Kunming, were investigated from June to November 2015, excluding those with adverse conditions that may impact the establishment of the growth standards. Weight, length (height) and head circumference were measured using unified measurement tools and measurement methods. The Lambda-Mu-Sigma method was employed to establish percentile and standard deviation score reference values of weight-for-age, length (height)-for-age, head circumference-for-age, weight-for-length (height) and body mass index (BMI)-for-age of the study population. The standard deviation score curves of the new-established growth standards were compared with the 2009 reference standards. Results: Reference values of percentile (P3, P10, P25, P50, P75, P90, P97) and standard deviation score (-3, -2, -1, 0,+1,+2,+3) of weight-for-age, length (height)-for-age, head circumference-for-age, weight-for-length (height) and BMI-for-age were obtained. Compared with the 2009 growth standards, the difference of weight at P50 was -0.1-0.4 kg, the difference of length (height) at P50 was 0.1-1.3 cm, the difference of head circumference at P50 was -0.2-0.2 cm, the difference of weight for length (height) at P50 was -0.2-0.5 kg, and the difference of BMI at P50 was -0.2-0.2 kg/m2. The main differences were as follows: weight for girls aged 5.0-<7.0 years was 0.4-0.6 kg higher at +2 s, height for boys and girls aged 2.0-<7.0 years was 0.4-1.4 cm higher at -2 s, and BMI for boys and girls aged 5.0-<7.0 years was 0.1-0.3 kg/m2 higher at +2 s than the 2009 reference standards. Conclusion: The newly established growth standards for Chinese children under 7 years of age that have achieved a minor revision to the 2009 reference standards, are recommended for nationwide use in growth monitoring and nutritional assessment.
Male
;
Female
;
Child
;
Humans
;
Infant
;
Child Development
;
Body Weight
;
Cross-Sectional Studies
;
East Asian People
;
Body Height
;
China/epidemiology*
;
Reference Standards
;
Reference Values
;
Body Mass Index
9.Selection and validation of reference genes for quantitative real-time PCR analysis in Paeonia veitchii.
Meng-Ting LUO ; Jun-Zhang QUBIE ; Ming-Kang FENG ; A-Xiang QUBIE ; Bin HE ; Yue-Bu HAILAI ; Wen-Bing LI ; Zheng-Ming YANG ; Ying LI ; Xin-Jia YAN ; Yuan LIU ; Shao-Shan ZHANG
China Journal of Chinese Materia Medica 2023;48(21):5759-5766
Paeonia veitchii and P. lactiflora are both original plants of the famous Chinese medicinal drug Paeoniae Radix Rubra in the Chinese Pharmacopoeia. They have important medicinal value and great potential in the flower market. The selection of stable and reliable reference genes is a necessary prerequisite for molecular research on P. veitchii. In this study, two reference genes, Actin and GAPDH, were selected as candidate genes from the transcriptome data of P. veitchii. The expression levels of the two candidate genes in different tissues(phloem, xylem, stem, leaf, petiole, and ovary) and different growth stages(bud stage, flowering stage, and dormant stage) of P. veitchii were detected using real-time fluorescence quantitative technology(qRT-PCR). Then, the stability of the expression of the two reference genes was comprehensively analyzed using geNorm, NormFinder, BestKeeper, ΔCT, and RefFinder. The results showed that the expression patterns of Actin and GAPDH were stable in different tissues and growth stages of P. veitchii. Furthermore, the expression levels of eight genes(Pv-TPS01, Pv-TPS02, Pv-CYP01, Pv-CYP02, Pv-CYP03, Pv-BAHD01, Pv-UGT01, and Pv-UGT02) in different tissues were further detected based on the transcriptome data of P. veitchii. The results showed that when Actin and GAPDH were used as reference genes, the expression trends of the eight genes in different tissues of P. veitchii were consistent, validating the reliability of Actin and GAPDH as reference genes for P. veitchii. In conclusion, this study finds that Actin and GAPDH can be used as reference genes for studying gene expression levels in different tissues and growth stages of P. veitchii.
Real-Time Polymerase Chain Reaction/methods*
;
Paeonia/genetics*
;
Actins/genetics*
;
Reproducibility of Results
;
Transcriptome
;
Glyceraldehyde-3-Phosphate Dehydrogenases/genetics*
;
Reference Standards
;
Gene Expression Profiling/methods*
10.Clinical comprehensive evaluation of Ruyi Zhenbao Pills in treatment of osteoarthritis.
Xu-Ming ZHANG ; Chun-Quan SUN ; Xiao-Xiao ZHAO ; Jun-Yu XI ; Yi LIU ; Yan-Ming XIE
China Journal of Chinese Materia Medica 2023;48(21):5957-5964
This study evaluated the clinical effectiveness of Ruyi Zhenbao Pills in the treatment of osteoarthritis, aiming to clarify its clinical advantages and promote rational drug use and related policy transformation. Following the relevant standards in Guidelines for the Comprehensive Evaluation of Drugs in Clinical Practice and Technical Specifications for the Clinical Comprehensive Evaluation of Chinese Patent Medicine, comprehensive research and related data on Ruyi Zhenbao Pills in the treatment of osteoarthritis were collected in the dimensions of safety, effectiveness, economy, innovation, suitability, accessibility, and traditional Chinese medicine(TCM) cha-racteristics(referred to as the "6+1" dimensions). Through evidence-based medicine, questionnaire surveys, health technology assessment, pharmacoeconomic evaluation, and other methods, a multi-criteria decision analysis(MCDA) model and CSC v2.0 software were used to comprehensively evaluate the clinical value of Ruyi Zhenbao Pills. Spontaneous reporting system data on adverse reactions and literature data indicate that the adverse reactions of Ruyi Zhenbao Pills are mostly general adverse reactions, with no reports of se-rious adverse reactions. The known risks are small, and its safety is rated as class A. It has been shown to effectively relieve joint pain and restore joint function in the treatment of osteoarthritis. However, more high-quality, large-sample randomized controlled trials are needed to further validate its effectiveness, which is rated as class B. There is evidence supporting its economic viability, and its economic is rated as class B. It demonstrates good clinical innovation, innovative enterprise service system, and industrial innovation, and innovation is rated as class A. Medical professionals and patients have a favorable perception of the suitability of Ruyi Zhenbao Pills, and further improvement can be made in terms of convenience of administration and promotion to facilitate rational drug use by healthcare professionals and patients. Suitability is rated as class B. The drug has a favorable price level, availability, and affordability, and accessibility is rated as class A. Ruyi Zhenbao Pills are a classic Tibetan medicinal prescription with excellent TCM theoretical characteristics. However, further research is needed on its use in human studies. TCM characteristics are rated as class B. Based on the evaluation results of the "6+1" dimensions, the comprehensive clinical evaluation is rated as grade B. Ruyi Zhenbao Pills have good clinical value in the treatment of osteoarthritis, and it is recommended to undergo the necessary procedures for conditional transformation into a policy for the management of essential clinical drugs.
Humans
;
Medicine, Chinese Traditional
;
Reference Standards
;
Nonprescription Drugs
;
Drugs, Essential
;
Osteoarthritis/drug therapy*
;
Drugs, Chinese Herbal/adverse effects*


Result Analysis
Print
Save
E-mail